Bydureon BCise® (exenatide extended-release) – Expanded indication
July 23, 2021 - The FDA approved AstraZeneca’s Bydureon BCise (exenatide extended-release), as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus (T2DM).
Top